Mr. Rod Matheson reports

MARVEL BIOSCIENCES SECURES FINANCIAL AND STRATEGIC INVESTMENT WITH 5 HORIZON VENTURES

Marvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc., have secured financial and strategic support from 5 Horizons Ventures for the company's upcoming phase 1 clinical trial of its lead drug candidate, MB-204.

5 Horizons Ventures is a specialized life sciences investment and advisory firm with relationships across global clinical research organizations that partners with biotech companies during the critical in-human clinical trial phase, providing capital and strategic support to advance innovative therapies. Through pivotal capital investments, strategic partnerships and intellectual property evaluation and validation, 5 Horizons Ventures empowers the development of transformative therapies and drives new treatments through rigorous testing, validation and optimization.

Marvel's phase 1 program, which will be developed in collaboration with Contract Research Organization (CRO) partner Novotech, will evaluate MB-204's potential to treat neurodevelopmental disorders such as Rett syndrome and Fragile X, as well as autism spectrum disorder and depression. The partnership is expected to combine Marvel's lead asset, Novotech's expertise in early phase clinical trials and 5 Horizons' financial and strategic resources to accelerate MB-204's development. Under the terms of the partnership, 5 Horizons Ventures will contribute financing equivalent to 15 per cent of the company's CRO costs associated with Marvel's upcoming phase 1 clinical trial of MB-204. This non-dilutive support is designed to reduce upfront capital requirements while accelerating the company's transition into human clinical studies.

"We've been conducting due diligence with the Marvel team over the past year and we're excited to provide an investment for the phase 1 trial of MB-204," said Aaron Ray, managing partner of 5 Horizons Ventures. "We believe the combination of the Marvel team, preclinical data, and multiple indications in both rare disease and the central nervous system positions the company for success. We also believe the FDA's recent announcement providing the framework supporting rare diseases will help accelerate the development process."

The phase 1 trial, expected to commence in the second quarter of 2026, will evaluate the safety, tolerability and pharmacokinetics of MB-204 in healthy subjects. MB-204 is a novel fluorinated derivative of an FDA-approved adenosine A2A receptor antagonist and has demonstrated compelling preclinical efficacy across multiple central nervous system indications, including autism spectrum disorder, Rett syndrome and Fragile X syndrome.

"This partnership with 5 Horizons represents another important validation of Marvel's clinical and commercial strategy," said Rod Matheson, chief executive officer of Marvel Biosciences. "By securing participation in our clinical development costs from a group deeply embedded within the global CRO ecosystem, we are not only strengthening our capital efficiency but also aligning with partners who bring strategic insight into clinical execution and financing pathways."

The agreement builds on a series of recent milestones that underscore growing momentum for the company, including non-dilutive funding support from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) and Alberta Innovates CarE (AICE), as well as newly granted patents in key jurisdictions including the United States and Japan.

About Marvel Biosciences Corp.

Marvel Biosciences, through its wholly owned subsidiary Marvel Biotechnology Inc., is a Calgary-based biotechnology company developing new treatments for neurological diseases and neurodevelopmental disorders.

We seek Safe Harbor.